Life-cycle development Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentation
Life-cycle development Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
Life-cycle development Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Life-cycle development Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
Life-cycle development Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
Life-cycle development Helsinn publishes results from a secondary analysis of a Phase 3 trial in patients with CINV in The Oncologist
